Difference between revisions of "Team:BGU Israel"
Line 154: | Line 154: | ||
</center> | </center> | ||
</td></tr></table> | </td></tr></table> | ||
− | + | <br /><br /><br /><br /> | |
− | </ | + | <!-- finish HERE -----------------------------------------------------------------------------------------------> |
− | </ | + | |
− | </ | + | |
− | < | + | |
</div> | </div> | ||
Line 165: | Line 162: | ||
</div> | </div> | ||
<div class="visualClear"></div> | <div class="visualClear"></div> | ||
− | + | <br /><br /><br /><br /><br /><br /><br /><br /> | |
</html> | </html> | ||
{{BGU_Israel/footer}} | {{BGU_Israel/footer}} |
Revision as of 09:08, 18 September 2015
The Boomerang system: synthetic machine for cancer therapy
Despite recent treatment advancements, cancer is still a major cause of mortality worldwide. One of the fundamental problems preventing the development of effective therapy is the difficulty to target cancer cells exclusively.
In Boomerang, we're engineering a genetic device based on a simple concept of AND logic gate: the activation of our CRISPR/Cas9-based system is dependent on the existence of two cancer-specific promoters that control the expression of Cas9 and gRNA, and the combination of these two will occur only in cancer cells. CRISPR/Cas9 system allows several applications of Boomerang: 1) disruption of genes essential for cancer survival; and 2) activation of suicide genes, or color proteins for cancer cell detection (e.g., for complete surgical removal).
Our system can be potentially designed according to unique characteristics of a patient's tumor, paving the way to personalized medicine. We hope that our strategy will change the approach to cancer treatments.
|
Follow us:
Address:
Ben Gurion 1, Beer Sheva 8410501, Israel
Mail: igembgu2015@gmail.com